Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

As shown in Table 3 and Figure 1 , there are no significant differences in drug survival in the different types of SpA, although the group of "other SpA," which includes reactive arthritis, juvenile SpA, and chronic seronegative oligoarthritis, has lower drug survival (yet due to the small size of the group did not reach statistical significance [ n = 42]).

also in 111,027 other papers